Published: 2017-01-02

Analysis of price variation amongst different formulations of anxiolytic drugs available in Indian market

Vihang S. Chawan, Sagar V. Badwane, Kalpesh V. Gawand, Maheshi U. Chhaya


Background: Cost of drug therapy is a very serious issue for people belonging to lower economic status in India. A single drug is manufactured by various pharmaceutical companies and sold under different brand names. The prices of these drugs vary in the Indian market. Anxiety is a symptom of many psychiatric disorders and surgical conditions for which anxiolytic drugs are commonly prescribed. This study was planned to study the price variation amongst the different brands of anxiolytic drugs available in India.

Methods: Price of anxiolytic drugs manufactured by different pharmaceutical companies, in the same strength and dosage forms were obtained from “current index of medical specialties” Jan-April 2016 and “Indian drug review” Vol. XXII, Issue No.1, 2016. The difference in the maximum and minimum price of the same drug manufactured by different pharmaceutical companies and percentage variation in price per 10 tablets was calculated.

Results: Out of 26 single drug formulations analyzed, maximum percentage variation in prices were seen with diazepam (5 mg) 371.42% followed by clonazepam (0.5 mg) 350%, lorazepam (1 mg) 328.57%, alprazolam (0.25 mg) 320% and clobazam (20 mg) 318.18% and out of 7 combination drug formulations analyzed, maximum percentage variation in prices were seen with the combination of chlordiazepoxide + amitriptyline (10 + 25 mg) 230.07% followed by combination of trifluperazine + trihexiphenidyl (5 + 2 mg) 150%.

Conclusions: There is a wide variation in the price of different brands of anxiolytic drugs available in Indian market. Government of India should reduce the pricing of drugs by bringing them under drug pricing control order (DPCO).



Anxiolytic drugs, Price variation, Drug formulations, Pharmaceutical companies, DPCO

Full Text:



Rataboli PV, Garg A. Confusing brand names: the nightmare of medical profession. J Postgrad Med. 2005;51:13-6.

Das SC, Mandal M, Mandal SC. A critical study on availability and price variation between different brands: impact on access to medicines. Indian J Pharm Sci. 2007;69(1):160-3.

Frazier LM, Brown JT, Divine GW, Fleming GR, Philips NM, Siegal WC, et al. Can physician education lower the cost of prescription drugs? A prospective, controlled trial. Ann Intern Med. 1991;115(2):116-21.

Gazette of India–Extraordinary Part II-Sec.3 (ii). Drugs price control order. New Delhi. Ministry of Chemicals and Fertilizers, Department of Pharmaceuticals (National Pharmaceuticals Pricing Authority). Available from: http://www. As Accessed on 14 Apr 2016.

O’Donnell JM, Shelton RC. Drug therapy of depression and anxiety disorders. In: Brunton LL, Chabner BA, Knollmann BC, Editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 12th Ed. New York, NY: McGraw-Hill; 2011: 397-415.

Satoskar RS, Bhandarkar SD, Rege NN. Psychopharmacology – 2: Anxiolytics, Antidepressants and Mood Modifying Agents. In: Satoskar RS, Bhandarkar SD, Rege NN, Editors.. Pharmacology and Pharmacotherapeutics, 24th Edition. New Delhi: Elsevier Ltd; 2015: 208 -30.

Chawan VS, Gawand KV, Badwane SV. Cost analysis of oral hypolipidemic agents available in India. Int J Basic Clin Pharmacol. 2014;3:1-4.

Phatak AM, Hotwani JH, Deshmukh KR, Panchal SS, Naik MS. Cost analysis of long established and newer oral antiepileptic drugs available in the Indian market. Int J Med Res Health Sci. 2015;4(4):744-8.

Chawan VS, Gawand KV, Badwane SV. Fluoroquinolones in India -are we prescribing it right: A cost variation study. Natl J Physiol Pharm Pharmacol. 2015;5:306-8.

Indian Brand Equity Foundation. Introduction: Indian Pharmaceutical Industry. Available at As Accessed 14 April 2016.

Thomas M. Rational drug use and essential drug concept. In: Parthasarthi G, Nyfort-Hasen K, Editors. A textbook of clinical pharmacy practice. 1st ed. Himayatnagar, Hyderabad: Orient Longman; 2004. p. 72-3.

Sarkar PK. A rational drug policy. Indian J Med Ethics. 2004;1:30-5.

Roy V, Rewari S. Ambiguous drug pricing: a physician’s dilemma. Indian J Pharmacol. 1998;30:404-7.

Wertheimer AI, Grumer SK. Overview of international pharmacy pricing. Pharmacoeconomics. 1992;2:449-55.

Berki SE, Richards JW, Weeks HA. The mysteries of prescription pricing in retail pharmacies. Med Care. 1977;15:241-50.